AU2001249091A1 - Novel methods using cholinesterase inhibitors - Google Patents
Novel methods using cholinesterase inhibitorsInfo
- Publication number
- AU2001249091A1 AU2001249091A1 AU2001249091A AU4909101A AU2001249091A1 AU 2001249091 A1 AU2001249091 A1 AU 2001249091A1 AU 2001249091 A AU2001249091 A AU 2001249091A AU 4909101 A AU4909101 A AU 4909101A AU 2001249091 A1 AU2001249091 A1 AU 2001249091A1
- Authority
- AU
- Australia
- Prior art keywords
- cholinesterase inhibitors
- novel methods
- cholinesterase
- inhibitors
- donepezil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000544 cholinesterase inhibitor Substances 0.000 title abstract 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 abstract 2
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 229960003530 donepezil Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to cholinesterase inhibitors such a donepezil for the treatment of cognitive impairments associated with or caused by chemotherapy
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18674400P | 2000-03-03 | 2000-03-03 | |
US60186744 | 2000-03-03 | ||
US19761000P | 2000-04-18 | 2000-04-18 | |
US60197610 | 2000-04-18 | ||
US22078300P | 2000-07-25 | 2000-07-25 | |
US60220783 | 2000-07-25 | ||
US25922601P | 2001-01-03 | 2001-01-03 | |
US60259226 | 2001-01-03 | ||
PCT/US2001/007027 WO2001066114A1 (en) | 2000-03-03 | 2001-03-05 | Novel methods using cholinesterase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001249091A1 true AU2001249091A1 (en) | 2001-09-17 |
Family
ID=27497683
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001249091A Abandoned AU2001249091A1 (en) | 2000-03-03 | 2001-03-05 | Novel methods using cholinesterase inhibitors |
Country Status (11)
Country | Link |
---|---|
US (7) | US20020035128A1 (en) |
EP (5) | EP1311272B1 (en) |
JP (1) | JP2003525903A (en) |
AT (1) | ATE345803T1 (en) |
AU (1) | AU2001249091A1 (en) |
CY (1) | CY1107997T1 (en) |
DE (1) | DE60124730T2 (en) |
DK (1) | DK1311272T3 (en) |
ES (1) | ES2275670T3 (en) |
PT (1) | PT1311272E (en) |
WO (1) | WO2001066114A1 (en) |
Families Citing this family (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2275670T3 (en) * | 2000-03-03 | 2007-06-16 | EISAI R&D MANAGEMENT CO., LTD. | NEW METHODS USING CHOLESTERASE INHIBITORS. |
US20060183776A9 (en) * | 2000-03-03 | 2006-08-17 | Eisai Co., Ltd. | Liquid dosage formulations of donepezil |
US20030153598A1 (en) * | 2000-07-25 | 2003-08-14 | Raymond Pratt | Methods for treating Parkinson's disease with cholinesterase inhibitors |
JP2004532200A (en) * | 2001-03-15 | 2004-10-21 | サエジス ファーマシューティカルズ, インコーポレイテッド | Methods for restoring cognitive function after systemic stress |
MXPA04001959A (en) * | 2001-08-30 | 2005-02-17 | Johnson & Johnson | Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors. |
WO2003032914A2 (en) * | 2001-10-17 | 2003-04-24 | Eisai Co., Ltd. | Methods for treating substance abuse with cholinesterase inhibitors |
WO2003061658A1 (en) * | 2002-01-22 | 2003-07-31 | Eisai Co., Ltd. | Sigma receptor binder containing indanone derivative |
US20030162770A1 (en) * | 2002-02-22 | 2003-08-28 | Davis Bonnie M. | Use of modulators of nicotinic receptors for treatment of cognitive dysfunction |
AU2003298514A1 (en) * | 2002-05-17 | 2004-05-04 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
US20070053976A1 (en) * | 2002-05-17 | 2007-03-08 | Eisai R & D Management Co., Ltd. | Novel combination of drugs as antidepressant |
AU2003256644A1 (en) * | 2002-07-22 | 2004-02-09 | Duke University | Cholinergic therapy for individuals with learning disabilities |
AU2003287433A1 (en) * | 2002-11-01 | 2004-06-07 | Oregon Health And Science University | Treatment of hyperkinetic movement disorder with donepezil |
CA2516618A1 (en) * | 2003-02-27 | 2004-09-10 | Shirankai Kyoto University Faculty Of Medicine Alumni Association Inc. | Pharmaceutical composition for treatment of drug dependence |
EA200701782A3 (en) | 2003-04-24 | 2008-04-28 | Инсайт Корпорейшн | DERIVATIVES OF AZASPYROALKANES AS METHOD PROTEASIS INHIBITORS |
IL155666A (en) * | 2003-04-29 | 2013-12-31 | Neurim Pharma 1991 | Composition for treating insomnia |
US9119846B2 (en) * | 2003-04-29 | 2015-09-01 | Neurim Pharmaceuticals (1991) Ltd. | Method and composition for enhancing cognition in alzheimer's patients |
CN1826105B (en) * | 2003-05-23 | 2010-09-08 | 认知医药品有限责任公司 | Use of amphetamine composition in producing medicine for treating cognitive impairment |
MXPA05013960A (en) | 2003-06-17 | 2006-02-24 | Pfizer | N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenaline re-uptake inhibitors. |
EP1666066A4 (en) * | 2003-09-19 | 2007-03-28 | Eisai R&D Man Co Ltd | Remedy for down syndrome |
WO2005065645A2 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Donepezil formulations |
CA2555367A1 (en) * | 2004-01-22 | 2005-08-11 | Genaissance Pharmaceuticals, Inc. | Apoe genetic markers associated with age of onset of alzheimer's disease |
CA2554600A1 (en) * | 2004-01-26 | 2005-08-11 | Cortex Pharmaceuticals Inc. | Enhancement of ampakine-induced facilitation of synaptic responses by cholinesterase inhibitors |
EP1718294A4 (en) * | 2004-01-30 | 2007-10-03 | Axonyx Inc | Methods for treatment of complications of diabetes |
US20070293539A1 (en) * | 2004-03-18 | 2007-12-20 | Lansbury Peter T | Methods for the treatment of synucleinopathies |
CA2559282A1 (en) * | 2004-03-18 | 2005-09-29 | Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
US20050272722A1 (en) * | 2004-03-18 | 2005-12-08 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
US20060106060A1 (en) * | 2004-03-18 | 2006-05-18 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies (Lansbury) |
EP1744751A4 (en) * | 2004-03-18 | 2010-03-10 | Brigham & Womens Hospital | Methods for the treatment of synucleinopathies |
TW200533371A (en) * | 2004-04-15 | 2005-10-16 | Dainippon Pharmaceutical Co | Medicament comprising a combination of an acetylcholinesterase inhibitor and a 5-substituted-3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivative |
US20060135507A1 (en) * | 2004-08-13 | 2006-06-22 | Osamu Yokoyama | Therapeutic agent for overactive bladder involved in aging |
WO2006036936A2 (en) * | 2004-09-27 | 2006-04-06 | Bridge Pharma, Inc. | The s-isomer of 2-{2-[n-(2-indanyl)-n-phenylamino]ethyl}piperidine and other dermal anesthetic agents |
US20060079558A1 (en) * | 2004-09-27 | 2006-04-13 | Bridge Pharma. Inc. | R-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine and other dermal anesthetics |
US20060270709A1 (en) * | 2005-04-04 | 2006-11-30 | Eisai Co. Ltd. | Dihydropyridine compounds and compositions for headaches |
GB0605544D0 (en) * | 2006-03-20 | 2006-04-26 | Univ Nottingham | Genetic Markers For Alzheimer Disease |
US7858611B2 (en) * | 2006-05-09 | 2010-12-28 | Braincells Inc. | Neurogenesis by modulating angiotensin |
US7910108B2 (en) * | 2006-06-05 | 2011-03-22 | Incyte Corporation | Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases |
US7592458B2 (en) * | 2006-07-21 | 2009-09-22 | Wright George E | Dermal anesthetic compounds and pharmaceutical compositions for inducing local anesthesia and mitigating neuropathic pain |
US8012994B1 (en) | 2006-09-22 | 2011-09-06 | Sevastyanov Victor V | Method for the treatment of sensorineural hearing loss with donepezil hydrochloride (ARICEPT®) |
US20080131491A1 (en) * | 2006-12-01 | 2008-06-05 | Akinori Hanatani | Percutaneously absorbable preparation |
WO2008066185A1 (en) * | 2006-12-01 | 2008-06-05 | Nitto Denko Corporation | Method for prevention of discoloration with time of donepezil-containing skin adhesive preparation |
JP2010520154A (en) * | 2007-03-05 | 2010-06-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | AMPA receptor antagonists and NMDA receptor antagonists for neurodegenerative diseases |
WO2008139984A1 (en) * | 2007-04-26 | 2008-11-20 | Eisai R & D Management Co., Ltd. | Cinnamide compounds for dementia |
WO2008141081A1 (en) * | 2007-05-10 | 2008-11-20 | Amr Technology, Inc. | Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
WO2009058851A2 (en) * | 2007-10-31 | 2009-05-07 | Alseres Pharmaceuticals, Inc. | Methods for diagnosing and monitoring treatment of lewy body dementia by assessing dopamine transporter level |
US20090156561A1 (en) * | 2007-12-13 | 2009-06-18 | Seed John C | Use of Cholinesterase Inhibitors In Smoking Cessation |
WO2009151683A2 (en) * | 2008-03-12 | 2009-12-17 | Link Medicine Corporation | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications |
WO2009128058A1 (en) | 2008-04-18 | 2009-10-22 | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al | Psycho-pharmaceuticals |
US8461389B2 (en) | 2008-04-18 | 2013-06-11 | University College Dublin, National University Of Ireland, Dublin | Psycho-pharmaceuticals |
US20090291127A1 (en) * | 2008-05-21 | 2009-11-26 | Jianye Wen | Transdermal anti-dementia active agent formulations and methods for using the same |
US20110056863A1 (en) * | 2008-05-30 | 2011-03-10 | Junichi Sekiya | Adhesive preparation containing donepezil, and package of the same |
WO2009145269A1 (en) * | 2008-05-30 | 2009-12-03 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Transdermal preparation |
EP2328582A4 (en) * | 2008-09-30 | 2012-02-22 | Teikoku Pharma Usa Inc | Transdermal extended-delivery donepezil compositions and methods for using the same |
BRPI0920927A2 (en) * | 2008-11-13 | 2019-09-24 | Link Medicine Corp | azaquinolinone derivatives and uses thereof |
US20110060005A1 (en) * | 2008-11-13 | 2011-03-10 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
US20100331363A1 (en) * | 2008-11-13 | 2010-12-30 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
JP2012523437A (en) * | 2009-04-13 | 2012-10-04 | セラヴァンス, インコーポレーテッド | 5-HT4 receptor agonist compounds for the treatment of cognitive impairment |
US20100178307A1 (en) * | 2010-01-13 | 2010-07-15 | Jianye Wen | Transdermal anti-dementia active agent formulations and methods for using the same |
BR112012019923A2 (en) | 2010-02-09 | 2016-08-09 | Univ Johns Hopkins | methods and compositions for improving cognitive function |
EP2366378A1 (en) | 2010-03-01 | 2011-09-21 | Dexcel Pharma Technologies Ltd. | Sustained-release donepezil formulations |
WO2011127235A1 (en) | 2010-04-07 | 2011-10-13 | Eisai Inc. | Combination therapy for the treatment of dementia |
GR1007368B (en) | 2010-05-27 | 2011-08-02 | Alapis Α.Β.Ε.Ε., | Drinkable pharmaceutical solutions for the treatment of dementia symptoms |
WO2011151359A1 (en) | 2010-06-02 | 2011-12-08 | Noscira, S.A. | Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative |
US8980924B2 (en) | 2010-11-24 | 2015-03-17 | The Trustees Of Columbia University In The City Of New York | Non-retinoid RBP4 antagonist for treatment of age-related macular degeneration and stargardt disease |
US20120225922A1 (en) | 2011-03-04 | 2012-09-06 | Qr Pharma | Effective Amounts of (3aR)-1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo [2,3-b]indol-5-yl Phenylcarbamate and Methods of Treating or Preventing Neurodegeneration |
WO2013109543A1 (en) * | 2012-01-20 | 2013-07-25 | The Board Of Trustees Of The Leland Stanford Junior University | Small molecule cmklr1 antagonists in demyelinating disease |
US9333202B2 (en) | 2012-05-01 | 2016-05-10 | The Trustees Of Columbia University In The City Of New York | Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease |
CA2891122C (en) | 2012-11-14 | 2021-07-20 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
US9265458B2 (en) | 2012-12-04 | 2016-02-23 | Sync-Think, Inc. | Application of smooth pursuit cognitive testing paradigms to clinical drug development |
US9380976B2 (en) | 2013-03-11 | 2016-07-05 | Sync-Think, Inc. | Optical neuroinformatics |
WO2014151936A1 (en) | 2013-03-14 | 2014-09-25 | The Trustees Of Columbia University In The City Of New York | Octahydropyrrolopyrroles, their preparation and use |
EP3495357B1 (en) | 2013-03-14 | 2021-05-05 | The Trustees of Columbia University in the City of New York | 4-phenylpiperidines, their preparation and use |
US9938291B2 (en) | 2013-03-14 | 2018-04-10 | The Trustess Of Columbia University In The City Of New York | N-alkyl-2-phenoxyethanamines, their preparation and use |
US9637450B2 (en) | 2013-03-14 | 2017-05-02 | The Trustees Of Columbia University In The City Of New York | Octahydrocyclopentapyrroles, their preparation and use |
WO2014144663A1 (en) | 2013-03-15 | 2014-09-18 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
EP2968220B1 (en) | 2013-03-15 | 2021-05-05 | Agenebio, Inc. | Methods and compositions for improving cognitive function |
US9359315B2 (en) | 2013-09-10 | 2016-06-07 | Arrien Pharmaceuticals Llc | Substituted 2,3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis |
KR102429220B1 (en) | 2014-04-30 | 2022-08-04 | 더 트러스티이스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 | Substituted 4-phenylpiperidines, their preparation and use |
TWI698436B (en) | 2014-12-30 | 2020-07-11 | 美商佛瑪治療公司 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors |
MA41291A (en) | 2014-12-30 | 2017-11-07 | Forma Therapeutics Inc | PYRROLOTRIAZINONE AND IMIDAZOTRIAZINONE DERIVATIVES AS UBIQUE-SPECIFIC PROTEASE INHIBITORS No. 7 (USP7) FOR THE TREATMENT OF CANCER |
EP3253765A1 (en) | 2015-02-05 | 2017-12-13 | Forma Therapeutics, Inc. | Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors |
EP3253738A1 (en) | 2015-02-05 | 2017-12-13 | Forma Therapeutics, Inc. | Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors |
EP3253759A1 (en) | 2015-02-05 | 2017-12-13 | Forma Therapeutics, Inc. | Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors |
CN107810002B (en) | 2015-05-22 | 2021-01-05 | 艾吉因生物股份有限公司 | Extended release pharmaceutical compositions of levetiracetam |
DK3334425T3 (en) * | 2015-08-14 | 2021-02-22 | Qr Pharma | METHODS OF TREATMENT OR PREVENTION OF ACUTE BRAIN OR NERVE INJURIES |
CA3083015A1 (en) | 2017-05-24 | 2018-11-28 | Qr Pharma, Inc. | Prevention or treatment of disease states due to metal dis-homeostasis via administration of posiphen to healthy or sick humans |
JP2021501210A (en) | 2017-10-30 | 2021-01-14 | モントリオール ハート インスティテュート | How to Treat Elevated Plasma Cholesterol |
JP2022541021A (en) * | 2019-07-16 | 2022-09-21 | ラッシュ・ユニバーシティ・メディカル・センター | USING BENZOATE-CONTAINING COMPOSITIONS TO TREAT NEURODEGENERATIVE DISORDERS |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL74497A (en) * | 1985-03-05 | 1990-02-09 | Proterra Ag | Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives |
US4826843A (en) * | 1985-07-08 | 1989-05-02 | Bristol-Myers | Cerebral function enhancing diazinylpiperidine derivatives |
FI95572C (en) * | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Process for the preparation of a medicament useful as a piperidine derivative or its pharmaceutical salt |
JP2777159B2 (en) * | 1988-12-22 | 1998-07-16 | エーザイ株式会社 | Pharmaceuticals containing cyclic amine derivatives |
JP3075566B2 (en) | 1990-05-15 | 2000-08-14 | エーザイ株式会社 | Optically active indanone derivative |
JP2965675B2 (en) | 1990-11-21 | 1999-10-18 | エーザイ株式会社 | Method for producing (-)-1-benzyl-4-[(5,6-dimethoxy-1-indanone) -2-yl] methylpiperidine |
US5668117A (en) * | 1991-02-22 | 1997-09-16 | Shapiro; Howard K. | Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments |
EP0597956A1 (en) * | 1991-07-29 | 1994-05-25 | Warner-Lambert Company | Quinazoline derivatives as acetylcholinesterase inhibitors |
SE9103752D0 (en) * | 1991-12-18 | 1991-12-18 | Astra Ab | NEW COMPOUNDS |
TW513409B (en) | 1996-06-07 | 2002-12-11 | Eisai Co Ltd | Polymorphs of donepezil hydrochloride |
SK285312B6 (en) | 1996-06-07 | 2006-10-05 | Eisai Co., Ltd. | Polymorph (III) of donepezil hydrochloride, process for producing it and therapeutical composition containing the same |
WO1997046526A1 (en) | 1996-06-07 | 1997-12-11 | Eisai Co., Ltd. | Stable polymorphs of donepezil (1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine) hydrochloride and process for production |
US5965571A (en) * | 1996-08-22 | 1999-10-12 | New York University | Cholinesterase inhibitors for treatment of Parkinson's disease |
CA2282654C (en) | 1997-03-03 | 2009-02-03 | Eisai Co., Ltd. | Use of cholinesterase inhibitors to treat attention deficit hyperactivity disorder |
CA2304505A1 (en) * | 1997-09-24 | 1999-04-01 | Nova Molecular, Inc. | Methods for increasing apoe levels for the treatment of neurodegenerative disease |
DE69822218T2 (en) | 1997-12-05 | 2005-02-03 | Eisai Co., Ltd. | DONEPEZIL POLYCRYSTALS AND REQUIREMENTS FOR THEIR MANUFACTURE |
CA2316360C (en) | 1998-01-16 | 2007-09-18 | Eisai Co., Ltd. | Process for production of donepezil derivative |
US6193993B1 (en) | 1998-03-03 | 2001-02-27 | Eisai Co., Ltd. | Suppository containing an antidementia medicament |
KR100746753B1 (en) | 1998-08-28 | 2007-08-06 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | Medicinal compositions with relieved bitterness, etc. |
IT1304904B1 (en) | 1998-09-11 | 2001-04-05 | Eisai Co Ltd | ANTICOLINESTERASIC DERIVATIVES FOR THE TREATMENT OF FUNCTIONAL AND / OR ORGANIC SYNDROME |
WO2000059544A1 (en) | 1999-03-31 | 2000-10-12 | Eisai Co., Ltd. | Stabilized compositions containing nootropic drugs |
US20060183776A9 (en) * | 2000-03-03 | 2006-08-17 | Eisai Co., Ltd. | Liquid dosage formulations of donepezil |
US20030153598A1 (en) * | 2000-07-25 | 2003-08-14 | Raymond Pratt | Methods for treating Parkinson's disease with cholinesterase inhibitors |
ES2275670T3 (en) * | 2000-03-03 | 2007-06-16 | EISAI R&D MANAGEMENT CO., LTD. | NEW METHODS USING CHOLESTERASE INHIBITORS. |
AU2001239052A1 (en) | 2000-03-06 | 2001-09-17 | Immune Network Ltd. | Compositions for prevention and treatment of dementia |
US20010036949A1 (en) | 2000-05-09 | 2001-11-01 | Coe Jotham Wadsworth | Pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal |
WO2003024450A1 (en) | 2001-09-20 | 2003-03-27 | Eisai Co., Ltd. | Methods for treating prion diseases |
WO2003024456A1 (en) | 2001-09-20 | 2003-03-27 | Eisai Co., Ltd. | Methods for treating and preventing migraines |
WO2003032914A2 (en) | 2001-10-17 | 2003-04-24 | Eisai Co., Ltd. | Methods for treating substance abuse with cholinesterase inhibitors |
AU2003228796A1 (en) | 2002-05-01 | 2003-11-17 | Eisai Co., Ltd. | Cholinesterase inhibitors to prevent injuries caused by chemicals |
AU2003298514A1 (en) | 2002-05-17 | 2004-05-04 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
AU2003287433A1 (en) * | 2002-11-01 | 2004-06-07 | Oregon Health And Science University | Treatment of hyperkinetic movement disorder with donepezil |
-
2001
- 2001-03-05 ES ES01922272T patent/ES2275670T3/en not_active Expired - Lifetime
- 2001-03-05 EP EP01922272A patent/EP1311272B1/en not_active Expired - Lifetime
- 2001-03-05 WO PCT/US2001/007027 patent/WO2001066114A1/en active IP Right Grant
- 2001-03-05 EP EP09011084A patent/EP2133078A1/en not_active Withdrawn
- 2001-03-05 DK DK01922272T patent/DK1311272T3/en active
- 2001-03-05 EP EP09011085A patent/EP2140868A1/en not_active Withdrawn
- 2001-03-05 DE DE60124730T patent/DE60124730T2/en not_active Expired - Lifetime
- 2001-03-05 EP EP09011050A patent/EP2130538A1/en not_active Withdrawn
- 2001-03-05 EP EP09011051A patent/EP2138177A1/en not_active Withdrawn
- 2001-03-05 AT AT01922272T patent/ATE345803T1/en active
- 2001-03-05 JP JP2001564766A patent/JP2003525903A/en active Pending
- 2001-03-05 AU AU2001249091A patent/AU2001249091A1/en not_active Abandoned
- 2001-03-05 PT PT01922272T patent/PT1311272E/en unknown
- 2001-07-06 US US09/899,028 patent/US20020035128A1/en not_active Abandoned
- 2001-09-04 US US09/947,087 patent/US6482838B2/en not_active Expired - Fee Related
- 2001-09-04 US US09/947,086 patent/US6458807B1/en not_active Expired - Lifetime
-
2002
- 2002-01-25 US US10/054,931 patent/US6576646B1/en not_active Expired - Fee Related
- 2002-09-03 US US10/232,406 patent/US6689795B2/en not_active Expired - Fee Related
-
2003
- 2003-12-11 US US10/732,349 patent/US7563808B2/en not_active Expired - Fee Related
-
2005
- 2005-07-15 US US11/181,855 patent/US20050250812A1/en not_active Abandoned
-
2007
- 2007-01-29 CY CY20071100121T patent/CY1107997T1/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20020035129A1 (en) | 2002-03-21 |
DE60124730T2 (en) | 2007-10-04 |
DK1311272T3 (en) | 2007-02-26 |
JP2003525903A (en) | 2003-09-02 |
US20030040532A1 (en) | 2003-02-27 |
US6458807B1 (en) | 2002-10-01 |
WO2001066114A1 (en) | 2001-09-13 |
EP1311272A1 (en) | 2003-05-21 |
ES2275670T3 (en) | 2007-06-16 |
DE60124730D1 (en) | 2007-01-04 |
EP2140868A1 (en) | 2010-01-06 |
EP2138177A1 (en) | 2009-12-30 |
US6689795B2 (en) | 2004-02-10 |
EP1311272A4 (en) | 2003-05-21 |
EP2133078A1 (en) | 2009-12-16 |
US6576646B1 (en) | 2003-06-10 |
EP1311272B1 (en) | 2006-11-22 |
EP2130538A1 (en) | 2009-12-09 |
US20020035128A1 (en) | 2002-03-21 |
US20040122051A1 (en) | 2004-06-24 |
PT1311272E (en) | 2007-02-28 |
US20050250812A1 (en) | 2005-11-10 |
CY1107997T1 (en) | 2013-09-04 |
US7563808B2 (en) | 2009-07-21 |
US6482838B2 (en) | 2002-11-19 |
ATE345803T1 (en) | 2006-12-15 |
US20020040038A1 (en) | 2002-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001249091A1 (en) | Novel methods using cholinesterase inhibitors | |
AU2003225295A1 (en) | Substituted pyrroline kinase inhibitors | |
GB9722520D0 (en) | Compounds | |
YU42803A (en) | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms | |
JO2654B1 (en) | Polyarylcarboxamides useful as lipid lowering agents | |
AU2003285934A1 (en) | Analogs and prodrugs of buprenorphine | |
MXPA03005139A (en) | Macroheterocylic compounds useful as kinase inhibitors. | |
AU2003249983A1 (en) | Piperidines useful for the treatment of central nervous system disorders | |
IL163911A0 (en) | Naltrexone hydrochloride compositions | |
TW200500339A (en) | Pyrrolidine derivatives, and process for the preparation | |
TW200605871A (en) | Carboxamido opioid compounds | |
BG105009A (en) | Method for producing 4-carboxyamino-2-substituted 1,2,3,4-tetrahydroquinoline | |
ZA200404752B (en) | 6-aminomorphinane derivatives method for the production and use thereof | |
AU2001230395A1 (en) | Use of cox-2 inhibitors as gastroprokinetics | |
YU61103A (en) | Processes for the production of substituted 2- (2-pyridylmethyl)sulfinyl-1h-benzimidazoles | |
GB0322510D0 (en) | Novel compounds | |
BG105953A (en) | Method for treating copd | |
WO2002076396A3 (en) | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases | |
PT1206452E (en) | PREPARATION PROCESS OF BENZOPER-HYDROISOINDOLE COMPOUNDS | |
AU2003246694A1 (en) | Aryl piperidine derivatives as inducers of ldl-receptor expression for the treatment of hypercholesterolemia | |
AU2001297649A1 (en) | Tricyclic compounds and their analogs as inhibitors of cytokine signaling | |
IL144126A0 (en) | A method of altering the specificity of cyclooxygenase-inhibiting compounds | |
HK1051558A1 (en) | Method for the enzymatic resolution of the racemates of aminomethyl-aryl-cyclohexanol derivatives. | |
IL128028A0 (en) | Treatment of psychotic disorders | |
AU7652100A (en) | Method for extracting bacterio-rhodopsin |